Immunome, Inc.
NASDAQ:IMNM
Overview | Financials
| Company Name | Immunome, Inc. |
| Symbol | IMNM |
| Currency | USD |
| Price | 9.4 |
| Market Cap | 818,223,000 |
| Dividend Yield | 0% |
| 52-week-range | 5.15 - 16.73 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Clay B. Siegall Ph.D. |
| Website | https://immunome.com |
An error occurred while fetching data.
About Immunome, Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD





